相关实验视频

Updated: May 4, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

富可丁载入的固体脂质纳米颗粒在对抗高脂肪饮食诱导的小鼠肥胖症方面发挥了强大的治疗效果

Lijun Ding1, Xiao Luo2, Weijia Wen1,2,3

  • 1Thrust of Bioscience and Biomedical Engineering, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, China.

International journal of molecular sciences
|June 13, 2025
PubMed
概括

富可丁纳米颗粒通过显著减少体重和脂肪增加,有效地对抗肥胖. 这种配方改善了代谢健康,为肥胖和相关疾病提供了有前途的治疗策略.

关键词:
这是一种抗肥胖的药物.有效性 有效性 有效性.富可桑丁是一种富可桑丁.有高脂肪的饮食.固体脂质纳米粒子 (SLN) 是一种固体脂质纳米粒子.

更多相关视频

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

3.7K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

1.9K

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324